Stay updated on Poziotinib in NSCLC with EGFR/HER2 Insertion Clinical Trial
Sign up to get notified when there's something new on the Poziotinib in NSCLC with EGFR/HER2 Insertion Clinical Trial page.

Latest updates to the Poziotinib in NSCLC with EGFR/HER2 Insertion Clinical Trial page
- Check6 days agoChange DetectedThe study page now indicates recruitment is closed and results have been posted. New navigation/help sections were added (How to Read a Study Record, Common Questions, How to Join a Study), and the 28-day treatment cycle duration is stated.SummaryDifference6%

- Check13 days agoChange DetectedThe page shows a new revision label (v3.5.5), replacing the previous v3.5.4, signaling a minor backend or template update without changes to study data.SummaryDifference0.0%

- Check20 days agoChange DetectedRemoved the text '2024-01-26' and the label 'Certification/Extension First Posted' from the Study Record Dates section, updating the historical QC entries shown for this study record. This change updates what is visible in the record’s QC history without altering the study data or eligibility.SummaryDifference0.1%

- Check27 days agoNo Change Detected
- Check35 days agoChange Detected- The page revision tag was updated from v3.5.3 to v3.5.4, signaling a minor update to the page's underlying versioning. - There are no changes to the visible content or user-facing functionality.SummaryDifference0.0%

- Check56 days agoChange DetectedThe page footer was updated to show a new ClinicalTrials.gov release revision number (from v3.5.2 to v3.5.3).SummaryDifference0.0%

- Check63 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

Stay in the know with updates to Poziotinib in NSCLC with EGFR/HER2 Insertion Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Poziotinib in NSCLC with EGFR/HER2 Insertion Clinical Trial page.